AVALO THERAPEUTICS, INC. Stock Split Ratio
AVALO THERAPEUTICS, INC. (AVTX) had Stock Split Ratio of 0.42% as of 2023-12-28, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Equity
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2024-11-07
- 2023-12-28: Stockholders' Equity Note, Stock Split, Conversion Ratio 0.42%.
- 2022-07-07: Stockholders' Equity Note, Stock Split, Conversion Ratio 8.33%.
- 2015-09-01: Stockholders' Equity Note, Stock Split, Conversion Ratio 3.57%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2023-12-28 | 0.42% 10-Q · filed 2024-11-07 |
| 2022-07-07 | 8.33% 10-K · filed 2024-03-29 |
| 2015-09-01 | 3.57% 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |